Hierarchically structured microcapsules for oral delivery of emodin and tanshinone IIA to treat renal fibrosis

Sun, Jiang; Xu, Zhishi; Hou, Yu; Yao, Wenjie; Fan, Xudong; Zheng, Hua; Piao, Ji-Gang; Li, Fanzhu; Wei, Yinghui

doi:10.1016/j.ijpharm.2022.121490

Cited by 12 publications

(5 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To begin, 50 mg of lyophilized microgels was initially mixed with 50 mL of simulated gastric fluid (SGF, pH 1.2, containing 16.4 mL dilute hydrochloric acid and 10 g pepsin per 1 L water), which were placed in an oscillator (ZD-85, Lichen, China) with continued shaking at 37 °C [80]. After 2 h, microgels were collected and incubated in 50 mL simulated intestinal fluid (SIF, pH 6.8, containing 6.8 g potassium dihydrogen phosphate and 10 g pepsin per 1 L of water and adjusting with 0.1 M sodium hydroxide to pH 6.8) for 6 h, and 50 mL simulated intestinal fluid (SIF, pH 7.4, purchasing from Wokai Biotechnology Co., Ltd) for incubation for 16 h successively.…”

Section: In Vitro Release and Swelling Assessmentmentioning

confidence: 99%

Integrated oral microgel system ameliorates renal fibrosis by hitchhiking co-delivery and targeted gut flora modulation

Hou,

Zhu,

et al. 2024

J Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

Background Renal fibrosis is a progressive process associated with chronic kidney disease (CKD), contributing to impaired kidney function. Active constituents in traditional Chinese herbs, such as emodin (EMO) and asiatic acid (AA), exhibit potent anti-fibrotic properties. However, the oral administration of EMO and AA results in low bioavailability and limited kidney accumulation. Additionally, while oral probiotics have been accepted for CKD treatment through gut microbiota modulation, a significant challenge lies in ensuring their viability upon administration. Therefore, our study aims to address both renal fibrosis and gut microbiota imbalance through innovative co-delivery strategies. Results In this study, we developed yeast cell wall particles (YCWPs) encapsulating EMO and AA self-assembled nanoparticles (NPYs) and embedded them, along with Lactobacillus casei Zhang, in chitosan/sodium alginate (CS/SA) microgels. The developed microgels showed significant controlled release properties for the loaded NPYs and prolonged the retention time of Lactobacillus casei Zhang (L. casei Zhang) in the intestine. Furthermore, in vivo biodistribution showed that the microgel-carried NPYs significantly accumulated in the obstructed kidneys of rats, thereby substantially increasing the accumulation of EMO and AA in the impaired kidneys. More importantly, through hitchhiking delivery based on yeast cell wall and positive modulation of gut microbiota, our microgels with this synergistic strategy of therapeutic and modulatory interactions could regulate the TGF-β/Smad signaling pathway and thus effectively ameliorate renal fibrosis in unilateral ureteral obstruction (UUO) rats. Conclusion In conclusion, our work provides a new strategy for the treatment of renal fibrosis based on hitchhiking co-delivery of nanodrugs and probiotics to achieve synergistic effects of disease treatment and targeted gut flora modulation. Graphical Abstract

show abstract

Section: In Vitro Release and Swelling Assessmentmentioning

confidence: 99%

Integrated oral microgel system ameliorates renal fibrosis by hitchhiking co-delivery and targeted gut flora modulation

Hou,

Zhu,

et al. 2024

J Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

show abstract

“…To alleviate these limitations, Sun et al . 44 devised a novel nanomicrosystem-based co-delivery method by embedding Tan IIA-loaded nanoparticles (Tan IIA-NPs) into EMO-containing microcapsules with cell-penetrating peptides (CPPs) and polyethylene glycol (PEG) modifications to obtain CPP/PEG-NPs (Fig. 11).…”

Section: Drug Delivery Strategies For Renal Antifibrosismentioning

confidence: 99%

“…88 Tan IIA may act as an antirenal fibrosis agent along with emodin; nevertheless, inadequate oral absorption, unforeseen drug-drug interactions, and their potential to modify individual pharmacokinetic profiles when combined significantly restrict their utilization. To alleviate these limitations, Sun et al 44 devised a novel nanomicrosystem-based co-delivery method by embedding Tan IIA-loaded nanoparticles (Tan IIA-NPs) into EMO-containing microcapsules with cellpenetrating peptides (CPPs) and polyethylene glycol (PEG) modifications to obtain CPP/PEG-NPs (Fig. 11).…”

Section: Pharmacotherapymentioning

confidence: 99%

Advances in drug delivery-based therapeutic strategies for renal fibrosis treatment

Huang,

Lu,

Chen

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…Currently, anthraquinones have shown unique chemotherapeutic efficacy [ 116 ]. The development of nano-drug delivery technologies, in particular, has increased the bioavailability and targeting ability of anthraquinones [ 117 , 118 ]. Tanshinone IIA (Tan IIA), a diterpenoid quinone isolated from the botanical drug Salvia miltiorrhiza, modulates autophagy through regulating the Beclin1/LAMP1 and PI3K/Akt/mTOR signaling pathways.…”

Section: Natural Products Overcome Autophagy-mediated Tumor Drug Resi...mentioning

confidence: 99%

Focusing on the Role of Natural Products in Overcoming Cancer Drug Resistance: An Autophagy-Based Perspective

Yao

Feng

et al. 2022

Biomolecules

View full text Add to dashboard Cite

Autophagy is a critical cellular adaptive response in tumor formation. Nutritional deficiency and hypoxia exacerbate autophagic flux in established malignancies, promoting tumor cell proliferation, migration, metastasis, and resistance to therapeutic interventions. Pro-survival autophagy inhibition may be a promising treatment option for advanced cancer. Furthermore, excessive or persistent autophagy is cytotoxic, resulting in tumor cell death. Targeted autophagy activation has also shown significant promise in the fight against tumor drug resistance. Several research groups have examined the ability of natural products (NPs) such as alkaloids, terpenoids, polyphenols, and anthraquinones to serve as autophagy inhibitors or activators. The data support the capacity of NPs that promote lethal autophagy or inhibit pro-survival autophagy from being employed against tumor drug resistance. This paper discusses the potential applications of NPs that regulate autophagy in the fight against tumor drug resistance, some limitations of the current studies, and future research needs and priorities.

show abstract

Hierarchically structured microcapsules for oral delivery of emodin and tanshinone IIA to treat renal fibrosis

Cited by 12 publications

References 72 publications

Integrated oral microgel system ameliorates renal fibrosis by hitchhiking co-delivery and targeted gut flora modulation

Integrated oral microgel system ameliorates renal fibrosis by hitchhiking co-delivery and targeted gut flora modulation

Advances in drug delivery-based therapeutic strategies for renal fibrosis treatment

Focusing on the Role of Natural Products in Overcoming Cancer Drug Resistance: An Autophagy-Based Perspective

Contact Info

Product

Resources

About